Table 3.
HCTZ fixed-dose combination therapy | |||
Outcome measures | ARB/HCTZ | ACEI/HCTZ | BB/HCTZ |
Persistence (Odds Ratio, 95% CI) | 0.369a (0.356, 0.383) |
0.380a (0.368, 0.393) |
0.382a (0.370, 0.395) |
Adherence (Odds Ratio, 95% CI) | 0.457a (0.440, 0.475) |
0.495a (0.478, 0.513) |
0.398a (0.385, 0.412) |
PDC at end of follow-up period (Odds Ratio, 95% CI) | 0.388a (0.374, 0.403) |
0.415a (0.402, 0.429) |
0.435a (0.421, 0.449) |
MPR (HCTZ vs. fixed-dose) | 44.4 vs 61.0 Δ = -16.6b |
44.6 vs 57.5 Δ = -12.9b |
44.5 vs 61.5 Δ = -17.0b |
a Significant difference in outcome measures between pairwise comparison with HCTZ users at p < 0.05.
b p < 0.0001